SUPPRESSOR OF THE ENDOGENOUS INTERFERON- GAMMA

摘要

The invention relates to suppressor of the endogenous human interferon-gamma (hlFN-γ) applicable in treatment of diseases associated with impaired activity of endogenous hlFN-γ, especially autoimmune diseases and for prevention of graft arteriosclerosis and rejection of organs in allograft transplanted patients. It is based on inactive analogues of the hlFN-γwith pre-served affinity to the hlFN-γreceptor, genetically modified in the domain responsible for triggering the signal transduction pathway.